$HUMA: Humacyte, Inc. - Common Stock

Humacyte, Inc. is a clinical-stage biotechnology company focused on developing and commercializing Humacyte Vascular Allografts, a bioengineered vascular graft that can potentially address the chronic shortage of human vascular tissue. Humacyte's proprietary technology platform enables the company to produce acellular, or cell-free, vascular grafts that are structurally and functionally similar to native human vessels. This makes Humacyte Vascular Allografts a potential replacement for traditional vascular grafts, which are often rejected by the body or become blocked over time.

Humacyte Vascular Allografts are currently being evaluated in clinical trials for the treatment of a variety of vascular diseases, including coronary artery bypass grafting (CABG), peripheral artery disease (PAD), and abdominal aortic aneurysm (AAA). The company has completed two Phase 1/2 clinical trials of Humacyte Vascular Allografts for CABG, and is currently conducting a Phase 3 clinical trial for the treatment of PAD. Humacyte is also planning to initiate a Phase 3 clinical trial for the treatment of AAA in the near future.

If Humacyte Vascular Allografts are successfully commercialized, they could have a significant impact on the treatment of vascular diseases. Humacyte estimates that the global market for vascular grafts is worth over $10 billion, and the company believes that its products could capture a significant share of this market. Humacyte is also developing Humacyte Vascular Tissue, a bioengineered vascular tissue that could be used to repair or replace damaged or diseased blood vessels. Humacyte Vascular Tissue is currently in preclinical development, and the company plans to initiate clinical trials in the near future.

Humacyte is headquartered in San Diego, California, and the company has raised over $300 million in funding to date. The company's investors include OrbiMed Advisors, Versant Ventures, and MPM Capital. Humacyte is led by CEO Dan Hart, who has over 20 years of experience in the biotechnology industry.

Humacyte is a well-funded company with a promising technology platform. The company is developing products that have the potential to address a significant unmet need in the treatment of vascular diseases. If Humacyte is successful in commercializing its products, it could have a major impact on the healthcare industry.

Here are some additional details about Humacyte's technology and products:

• Humacyte Vascular Allografts are made from acellular human tissue that has been processed to remove all cells. This makes the grafts non-immunogenic, which means that they are less likely to be rejected by the body.
• Humacyte Vascular Allografts are structurally and functionally similar to native human vessels. This means that they can withstand the same stresses and strains as natural vessels, and they can promote the growth of new blood vessels.
• Humacyte Vascular Allografts are manufactured using a proprietary process that allows the company to produce grafts in a consistent and reproducible manner. This is important for ensuring the quality and safety of the grafts.
• Humacyte Vascular Allografts have been evaluated in a number of preclinical studies, and they have shown promise in a variety of applications. The company is currently conducting clinical trials of Humacyte Vascular Allografts for CABG, PAD, and AAA.

Humacyte is a leading company in the development of bioengineered vascular grafts. The company has a strong technology platform, a promising product pipeline, and a experienced management team. If Humacyte is successful in commercializing its products, it could have a major impact on the treatment of vascular diseases.